Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|23|10|1484-1494

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.10, 2017-05, pp. : 1484-1494

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PCSK9: an emerging target for treatment of hypercholesterolemia

By Duff Christopher J   Hooper Nigel M  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 2, 2011-02 ,pp. : 157-168

Informa Healthcare

Access to resources Recommend Favorite

Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkin's Lymphoma

By  

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 4, 2001-12 ,pp. : 301-311

Bentham Science Publishers

Access to resources Recommend Favorite

The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727

By Salam Amar M  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 10, 2012-10 ,pp. : 1585-1588

Informa Healthcare

Access to resources Recommend Favorite

Anti-Aggregating Antibodies, a New Approach Towards Treatment of Conformational Diseases

By  

Current Medicinal Chemistry, Vol. 9, Iss. 19, 2002-10 ,pp. : 1737-1749

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia

By Wierzbicki Anthony S   Hardman Timothy C   Viljoen Adie  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 5, 2012-05 ,pp. : 667-676

Informa Healthcare

Access to resources Recommend Favorite